Novel Homo-Bivalent and Polyvalent Compounds Based on Ligustrazine and Heterocyclic Ring as Anticancer Agents.
Antineoplastic Agents
/ chemical synthesis
Apoptosis
/ drug effects
Cell Cycle Checkpoints
/ drug effects
Cell Line, Tumor
Cell Proliferation
/ drug effects
Chromatography, High Pressure Liquid
Fluorescent Antibody Technique
Heterocyclic Compounds
/ chemistry
Humans
Membrane Potential, Mitochondrial
/ drug effects
Pyrazines
/ chemistry
Structure-Activity Relationship
antitumor
apoptosis
bivalency
cell cycle
polyvalency
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
09 Dec 2019
09 Dec 2019
Historique:
received:
07
11
2019
revised:
03
12
2019
accepted:
06
12
2019
entrez:
15
12
2019
pubmed:
15
12
2019
medline:
8
5
2020
Statut:
epublish
Résumé
Bivalent and polyvalent inhibitors can be used as antitumor agents. In this experiment, eight ligustrazine dimers and seven ligustrazine tetramers linked by alkane diamine with different lengths of carbon chain lengths were synthesized. After screening their antiproliferation activities against five cancer cell lines, most ligustrazine derivatives showed better cytotoxicity than the ligustrazine monomer. In particular, ligustrazine dimer
Identifiants
pubmed: 31835359
pii: molecules24244505
doi: 10.3390/molecules24244505
pmc: PMC6943434
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Heterocyclic Compounds
0
Pyrazines
0
tetramethylpyrazine
V80F4IA5XG
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : the national major science and technology special project for "significant new drugs development"
ID : 2018ZX09711001-005-018
Organisme : the medical and health science and technology innovation project of Chinese Academy of Medical Science
ID : 2017-I2M-3-021/2019-I2M-1-005
Organisme : the Tianjin special support program for talent development
ID : TJTZJH-GCCCXCYTD-1-30
Références
Biochim Biophys Acta. 2013 Jun;1830(6):3670-95
pubmed: 23428572
Biochem Biophys Res Commun. 2015 Jul 31;463(3):421-7
pubmed: 26043690
J Nat Prod. 1997 Apr;60(4):325-30
pubmed: 9134741
Molecules. 2012 Apr 30;17(5):4972-85
pubmed: 22547319
Adv Drug Deliv Rev. 2002 Mar 31;54(3):273-89
pubmed: 11922948
Bioorg Med Chem. 2009 Apr 15;17(8):3018-24
pubmed: 19329327
J Med Chem. 2016 Mar 10;59(5):1747-60
pubmed: 26891099
Org Biomol Chem. 2016 Jul 12;14(28):6611-37
pubmed: 27282396
Int J Mol Sci. 2015 Sep 02;16(9):21035-55
pubmed: 26404253
Eur J Med Chem. 2018 Jul 15;155:183-196
pubmed: 29886322
Int Immunopharmacol. 2015 May;26(1):212-20
pubmed: 25841319
Integr Cancer Ther. 2016 Jun;15(2):226-36
pubmed: 27179035
Eur J Med Chem. 2017 Apr 21;130:26-38
pubmed: 28237794
Curr Pharm Des. 2009;15(6):659-74
pubmed: 19199989
Chemistry. 2008;14(26):7738-47
pubmed: 18553325
Oncol Lett. 2018 Apr;15(4):4557-4563
pubmed: 29541225
Oncol Lett. 2013 Aug;6(2):583-589
pubmed: 24137375
Org Lett. 2001 May 31;3(11):1649-52
pubmed: 11405677
Cancer Epidemiol Biomarkers Prev. 1996 Sep;5(9):733-48
pubmed: 8877066
Adv Drug Deliv Rev. 2001 Mar 1;46(1-3):3-26
pubmed: 11259830
Eur J Med Chem. 2017 Jul 28;135:34-48
pubmed: 28431353
Chem Biol Drug Des. 2011 Oct;78(4):567-79
pubmed: 21736704
J Med Chem. 1997 Jan 31;40(3):261-6
pubmed: 9022792
Molecules. 2014 Nov 07;19(11):18215-31
pubmed: 25387350
Food Chem. 2012 May 1;132(1):43-50
pubmed: 26434261
J Med Chem. 2000 Oct 19;43(21):3867-77
pubmed: 11052792
J Cheminform. 2018 Jun 26;10(1):29
pubmed: 29943074